A State of the Art of Antioxidant Properties of Curcuminoids in Neurodegenerative Diseases

Int J Mol Sci. 2021 Mar 20;22(6):3168. doi: 10.3390/ijms22063168.

Abstract

Neurodegenerative diseases represent a set of pathologies characterized by an irreversible and progressive, and a loss of neuronal cells in specific areas of the brain. Oxidative phosphorylation is a source of energy production by which many cells, such as the neuronal cells, meet their energy needs. Dysregulations of oxidative phosphorylation induce oxidative stress, which plays a key role in the onset of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). To date, for most neurodegenerative diseases, there are no resolute treatments, but only interventions capable of alleviating the symptoms or slowing the course of the disease. Therefore, effective neuroprotection strategies are needed. In recent years, natural products, such as curcuminoids, have been intensively explored and studied for their therapeutic potentials in several neurodegenerative diseases. Curcuminoids are, nutraceutical compouns, that owen several therapeutic properties such as anti-oxidant, anti-inflammatory and neuroprotective effects. In this context, the aim of this review was to provide an overview of preclinical and clinical evidence aimed to illustrate the antioxidant effects of curcuminoids in neurodegenerative diseases. Promising results from preclinical studies encourage the use of curcuminoids for neurodegeneration prevention and treatment.

Keywords: anti-oxidant properties; curcuminoids; neurodegenerative diseases.

Publication types

  • Review

MeSH terms

  • Animals
  • Antioxidants / chemistry
  • Antioxidants / pharmacology*
  • Antioxidants / therapeutic use
  • Clinical Studies as Topic
  • Diarylheptanoids / chemistry
  • Diarylheptanoids / pharmacology*
  • Diarylheptanoids / therapeutic use
  • Disease Management
  • Disease Models, Animal
  • Disease Susceptibility
  • Drug Evaluation, Preclinical
  • Humans
  • Neurodegenerative Diseases / drug therapy
  • Neurodegenerative Diseases / etiology
  • Neurodegenerative Diseases / metabolism
  • Structure-Activity Relationship
  • Treatment Outcome

Substances

  • Antioxidants
  • Diarylheptanoids

Grants and funding